SequelSEC

NewAmsterdam Pharma Co N.V. NAMS

Pharmaceutical Preparations · CIK 0001936258 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$22.50M
Fiscal year ended 2025-12-31
Operating income
-$225.68M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

NewAmsterdam Pharma Co N.V. (NAMS) reported revenue of $22.50M and net income of -$203.82M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from NewAmsterdam Pharma Co N.V.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

NewAmsterdam Pharma Co N.V. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Revenue$22.50M$45.56M$14.09M$102.69M
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$225.68M-$176.29M-$182.97M-$3.56M
Net income-$203.82M-$241.60M-$176.94M-$22.63M
Research & development$141.83M$151.41M$159.42M$86.74M
Weighted-average diluted sharesshares 118.42Mshares 94.36Mshares 82.16Mshares 18.97M
Pretax income-$203.82M-$241.60M-$176.91M-$22.63M
Income tax expenseUnavailable-$1.00K$27.00KUnavailable
Diluted EPS$-1.72$-2.56$-2.15$-1.19
Selling, general & administrative$106.35M$70.45M$37.63M$19.51M
General & administrative$15.37M$14.44M$16.32M$13.59M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

NewAmsterdam Pharma Co N.V. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$490.00M$771.74M$340.45MUnavailable
Total assets$769.28M$864.62M$347.10M$478.50M
Current assets$675.70M$863.41M$346.79M$477.98M
Total liabilities$85.85M$107.12M$58.70M$48.43M
Current liabilities$85.79M$106.92M$49.90M$36.06M
Total equity incl. NCI$683.43M$757.50M$288.39M$430.07M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$8.97M$4.74M$16.92M$11.85M

Cash flow

NewAmsterdam Pharma Co N.V. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$147.78M-$158.56M-$141.22M$10.66M
Capital expendituresUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$174.92M-$62.85M-$24.00K-$221.00K
Financing cash flow$29.52M$659.51M$8.91M$391.90M
Net change in cashUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$59.42M$33.62M$24.57M$4.12M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$220.00K$113.00K$49.00K$9.00K

Derived

NewAmsterdam Pharma Co N.V. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating margin-1002.9%-386.9%-1298.6%-3.5%
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenue264.1%73.8%174.4%4.0%
Current ratio7.88x8.08x6.95x13.26x
Revenue YoY growth-50.6%223.4%-86.3%Unavailable
Net margin-905.7%-530.3%-1255.8%-22.0%
R&D / revenue630.3%332.3%1131.5%84.5%
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NAMS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-18View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.